JP2024521098A - ＳＡＲＳ－ＣｏＶ－２ポリペプチド - Google Patents

ＳＡＲＳ－ＣｏＶ－２ポリペプチド Download PDF

Info

Publication number
JP2024521098A
JP2024521098A JP2023571758A JP2023571758A JP2024521098A JP 2024521098 A JP2024521098 A JP 2024521098A JP 2023571758 A JP2023571758 A JP 2023571758A JP 2023571758 A JP2023571758 A JP 2023571758A JP 2024521098 A JP2024521098 A JP 2024521098A
Authority
JP
Japan
Prior art keywords
seq
amino acid
set forth
acid sequence
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521098A5 (enExample
Inventor
グレゴリー、エイ．ポーランド
インナ、ジー．オフシャンニコフ
リチャード、ビー．ケネディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Clinic in Florida
Original Assignee
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Clinic in Florida filed Critical Mayo Clinic in Florida
Publication of JP2024521098A publication Critical patent/JP2024521098A/ja
Publication of JP2024521098A5 publication Critical patent/JP2024521098A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023571758A 2021-05-20 2022-05-19 ＳＡＲＳ－ＣｏＶ－２ポリペプチド Pending JP2024521098A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163190964P 2021-05-20 2021-05-20
US63/190,964 2021-05-20
US202263341771P 2022-05-13 2022-05-13
US63/341,771 2022-05-13
PCT/US2022/030068 WO2022246084A1 (en) 2021-05-20 2022-05-19 Sars-cov-2 polypeptides

Publications (2)

Publication Number Publication Date
JP2024521098A true JP2024521098A (ja) 2024-05-28
JP2024521098A5 JP2024521098A5 (enExample) 2025-05-28

Family

ID=82321637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571758A Pending JP2024521098A (ja) 2021-05-20 2022-05-19 ＳＡＲＳ－ＣｏＶ－２ポリペプチド

Country Status (10)

Country Link
US (1) US12653880B2 (enExample)
EP (1) EP4294440A1 (enExample)
JP (1) JP2024521098A (enExample)
KR (1) KR20240012394A (enExample)
AU (1) AU2022277697A1 (enExample)
BR (1) BR112023024034A2 (enExample)
CA (1) CA3212678A1 (enExample)
IL (1) IL308465A (enExample)
MX (1) MX2023013665A (enExample)
WO (1) WO2022246084A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4547258A4 (en) * 2022-06-28 2026-08-05 Transcode Therapeutics Inc Matrix-Directed Rig-I Agonitor Nanoparticles and Precursor Compositions and Their Uses in Cancer Therapy
CN115947801B (zh) * 2022-12-29 2026-02-06 中国疾病预防控制中心病毒病预防控制所 一种流感病毒通用和冠状病毒联合多肽及其疫苗的应用
CN116143908B (zh) * 2023-02-10 2026-07-10 武汉华美生物工程有限公司 一种针对VLPs类型抗原免疫产生高效价抗血清的方法
WO2025231068A1 (en) * 2024-04-30 2025-11-06 The Regents Of The University Of Michigan Compositions and methods for enhancing systemic and mucosal immune responses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10954289B1 (en) * 2020-04-02 2021-03-23 Regeneren Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
WO2021204179A1 (en) * 2020-04-09 2021-10-14 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
WO2021214297A1 (en) * 2020-04-23 2021-10-28 Isa Pharmaceuticals B.V. Immunization against sars-cov-related diseases
US11191827B1 (en) * 2020-12-09 2021-12-07 Tevogen Bio Inc. COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19
WO2022023727A1 (en) * 2020-07-28 2022-02-03 Oxford University Innovation Limited Polypeptide panels and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013032421A2 (pt) 2011-06-29 2017-01-17 Immunotope Inc método para profilaxia ou tratamento de uma infecção pelo vírus da dengue, método para induzir uma resposta imune mediada por linfócito t citotóxico, vacina contra o vírus da dengue, método para prevenir uma doença causada pelo vírus da dengue e método para induzir uma resposta imune a pelo menos um vírus da dengue
WO2015130488A2 (en) 2014-02-28 2015-09-03 Immunotope, Inc. Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection
WO2015175361A1 (en) 2014-05-13 2015-11-19 Immunotope, Inc. Dengue virus specific multiple hla binding t cell epitopes for the use of universal vaccine development
EA201991377A1 (ru) 2017-01-03 2020-01-21 Эмерджекс Ваксинс Холдинг Лимитед Композиции универсальной вакцины против гриппа
SG11202002044WA (en) 2017-09-21 2020-04-29 Emergex Vaccines Holding Ltd MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus
JP2021509400A (ja) 2018-01-06 2021-03-25 イマージェクス ヴァクシンズ ホールディング リミテッドＥｍｅｒｇｅｘ Ｖａｃｃｉｎｅｓ Ｈｏｌｄｉｎｇ Ｌｉｍｉｔｅｄ 複数のフラビウイルスの予防および治療を目的としたｍｈｃクラスｉ関連ペプチド
AU2019244435A1 (en) 2018-03-29 2020-10-15 Emergex Vaccines Holding Limited Vaccine compositions
US20210283237A1 (en) 2018-03-29 2021-09-16 Emergex Vaccines Holding Limited Vaccine compositions
CA3099643A1 (en) 2018-05-18 2019-11-21 Emergex Vaccines Holding Limited Reverse peptide vaccine
GB202008250D0 (en) 2020-06-02 2020-07-15 Emergex Vaccines Holding Ltd Diagnosis, prevention and treatment of coronavirus infection
EP4294435A1 (en) 2021-02-16 2023-12-27 Emergex Vaccines Holding Limited Reverse peptides from coronavirus for immunogenic purposes
US20240269264A1 (en) 2021-06-02 2024-08-15 Emergex Vaccines Holding Limited Human coronavirus 229e derived peptides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10954289B1 (en) * 2020-04-02 2021-03-23 Regeneren Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
WO2021204179A1 (en) * 2020-04-09 2021-10-14 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
WO2021214297A1 (en) * 2020-04-23 2021-10-28 Isa Pharmaceuticals B.V. Immunization against sars-cov-related diseases
WO2022023727A1 (en) * 2020-07-28 2022-02-03 Oxford University Innovation Limited Polypeptide panels and uses thereof
US11191827B1 (en) * 2020-12-09 2021-12-07 Tevogen Bio Inc. COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAITLIN I. STODDARD ET AL., CELL REPORTS, vol. Vol. 35, Issue 8, Article number 109164, JPN6026008515, 25 May 2021 (2021-05-25), ISSN: 0005808094 *
CYRIELLE FOUGEROUX ET AL., NATURE COMMUNICATIONS, vol. Vol. 12, Article number 324, JPN6026008514, 12 January 2021 (2021-01-12), ISSN: 0005808093 *
DANIEL BIRTLES AND JINWOO LEE, BIOCHEMISTRY, vol. Vol. 60, Issue 40, JPN6026008516, 27 September 2021 (2021-09-27), pages 2978 - 2986, ISSN: 0005808095 *
HANS-GEORG RAMMENSEE ET AL., VACCINES, vol. Vol. 9, No. 5, Article number 428, JPN6026008513, 24 April 2021 (2021-04-24), ISSN: 0005808091 *
LEANA RICH DE MESA HERRERA, JOURNAL OF APPLIED PHARMACEUTICAL SCIENCE, vol. Vol. 11, Issue 3, JPN7026000896, 11 February 2021 (2021-02-11), pages 29 - 36, ISSN: 0005808092 *

Also Published As

Publication number Publication date
WO2022246084A1 (en) 2022-11-24
US12653880B2 (en) 2026-06-16
BR112023024034A2 (pt) 2024-02-06
IL308465A (en) 2024-01-01
MX2023013665A (es) 2024-01-08
AU2022277697A1 (en) 2024-01-04
CA3212678A1 (en) 2022-11-24
US20220370601A1 (en) 2022-11-24
KR20240012394A (ko) 2024-01-29
EP4294440A1 (en) 2023-12-27

Similar Documents

Publication Publication Date Title
Liu et al. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs
Sanchez-Felipe et al. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
Li et al. Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection
US20220370601A1 (en) SARS-CoV-2 POLYPEPTIDES
Simmons et al. Recent advances in dengue pathogenesis and clinical management
JP2023514249A (ja) コロナウイルス免疫原性組成物およびその使用
CN103476788A (zh) 免疫原性屈曲病毒肽
Frantz et al. A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters
Rainho-Tomko et al. Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle
Holzer et al. Immunogenicity and protective efficacy of seasonal human live attenuated cold-adapted influenza virus vaccine in pigs
Honda-Okubo et al. An Advax-CpG55. 2™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge
US12558415B2 (en) Broad-spectrum multi-antigen pan-coronavirus vaccine
WO2022023727A1 (en) Polypeptide panels and uses thereof
Wei et al. Generation and immunogenicity analysis of recombinant classical swine fever virus glycoprotein E2 and Erns expressed in baculovirus expression system
JP2021502115A (ja) 非構造タンパク質を含むジカウイルスキメラポリエピトープ、及び免疫原性組成物におけるその使用
Huang et al. Nipah virus attachment glycoprotein ectodomain delivered by type 5 adenovirus vector elicits broad immune response against NiV and HeV
US11040095B2 (en) Human rhinovirus vaccine
WO2023235863A1 (en) Live-attenuated sars-cov-2 vaccine
Shen et al. DNA vaccine prime and replicating vaccinia vaccine boost induce robust humoral and cellular immune responses against MERS-CoV in mice
EP4181955A1 (en) Methods and compositions for increasing immunity against coronaviruses
Li et al. The swine CD81 enhances E2-based DNA vaccination against classical swine fever
CN101921310A (zh) 登革病毒特异性hla-a2限制性表位肽及应用
CN117479954A (zh) SARS-CoV-2多肽
HK40107928A (en) Sars-cov-2 polypeptides
Dai et al. Production and characterization of Hantaan virus-like particles from baculovirus expression system

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260803